Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-Xa assays.

Summary, in English

Apixaban is an oral direct factor Xa inhibitor developed for prophylaxis and treatment of thromboembolic disorders. Laboratory monitoring is not necessary, but the effects on common coagulation reagents and assays are clinically valuable information.

• Author: Andreas Hillarp; Kerstin M Gustafsson; Lars Faxälv; Karin Strandberg; Fariba Baghaei; Inger Fagerberg Blixter; Maria Berndtsson; Tomas L Lindahl
• Department/s: Clinical Chemistry, Malmö
• Publishing year: 2014
• Language: English
• Pages: 1545-1553
• Publication/Series: Journal of Thrombosis and Haemostasis
• Volume: 12
• Issue: 9
• Links: http://www.ncbi.nlm.nih.gov/pubmed/24965851?dopt=Abstract; http://dx.doi.org/10.1111/jth.12649
• Document type: Journal article
• Publisher: Wiley-Blackwell
• Topic: Cardiac and Cardiovascular Systems
• Status: Published
• Research group: Clinical Chemistry, Malmö
• ISBN/ISSN/Other: ISSN: 1538-7933